Search
for
Sort by
Research 61–90 of 788
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- A review of Janus kinase inhibitor use in scarring alopecia
- Current and future pharmacotherapy for alopecia areata
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- A Novel Hope for Alopecia Totalis Patients: Case Report
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction
- Pharmacotherapy of alopecia areata
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Application of Baricitinib in Dermatology
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia